Am J Clin Oncol

1. BOUZIANE J, Loap P, Cao K, Allali S, et al
   Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: A Single-center Experience and Review of the Literature.
   Am J Clin Oncol. 2024 Jul 16. doi: 10.1097/COC.0000000000001135.
   

   >> Share

   
   

   
   Am J Epidemiol

2. ILLIPSE M, Gasparini A, Christoffersen B, Hall P, et al
   Studying the association Between longitudinal non-dense breast tissue and breast cancer risk: a joint modelling approach.
   Am J Epidemiol. 2024 Jul 11:kwae196. doi: 10.1093.
   

   >> Share

   
   

   
   Ann Surg Oncol

3. PARK KU, Showalter SL, Dirbas FM
   Surgical Perspectives on the Updated ASTRO Guideline on Partial Breast Irradiation for Breast Cancer.
   Ann Surg Oncol. 2024 Jul 13. doi: 10.1245/s10434-024-15639.
   

   >> Share

   
   
4. TORTORELLO GN, Shafique N, Keele L, Susman CG, et al
   Longitudinal Increases in Time to Surgery for Patients with Breast Cancer: A National Cohort Study.
   Ann Surg Oncol. 2024 Jul 13. doi: 10.1245/s10434-024-15723.
   

   >> Share

   
   
5. PRATT CG, Whitrock JN, Carter MM, Long SA, et al
   Implementation of Choosing Wisely((R)) Recommendations for Lymph Node Surgery in Male Breast Cancer.
   Ann Surg Oncol. 2024 Jul 20. doi: 10.1245/s10434-024-15811.
   

   >> Share

   
   
6. STRIJBOS BTM, Janssen L, Voogd AC, Zwaans WAR, et al
   ASO Visual Abstract: Persistent Pain After Breast Cancer Treatment, an Underreported Burden for Breast Cancer Survivors.
   Ann Surg Oncol. 2024 Jul 18. doi: 10.1245/s10434-024-15850.
   

   >> Share

   
   
7. GLENCER AC, Hunt KK, Teshome M
   ASO Author Reflections: Management of Inflammatory Breast Cancer: No Role for Surgical De-escalation Yet.
   Ann Surg Oncol. 2024 Jul 17. doi: 10.1245/s10434-024-15806.
   

   >> Share

   
   
8. LIMBERG JN, Hwang ES
   ASO Author Reflections: Trajectory of Subsequent Breast Cancer After Breast Atypia Diagnosis Suggests Need for Vigilant Follow-up.
   Ann Surg Oncol. 2024 Jul 17. doi: 10.1245/s10434-024-15869.
   

   >> Share

   
   
9. KRECKO LK, Neuman HB, Greenberg CC, Wilke LG, et al
   ASO Visual Abstract: Validation of the AJCC Eighth-Edition Breast Cancer Prognostic Staging System in Legacy Alliance Trials (AFT-01).
   Ann Surg Oncol. 2024 Jul 16. doi: 10.1245/s10434-024-15620.
   

   >> Share

   
   
10. DALTON JC, Crowell KA, Ntowe KW, van den Bruele AB, et al
    Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.
    Ann Surg Oncol. 2024 Jul 16. doi: 10.1245/s10434-024-15812.
    

    >> Share

    
    
11. BELLINI A, Keegan THM, Li Q, Maguire FB, et al
    Disparities in the Occurrence of Long-Term Effects of Bone Marrow Suppression after Treatment in Adolescent Young Adult Breast Cancer Survivors.
    Ann Surg Oncol. 2024 Jul 16. doi: 10.1245/s10434-024-15707.
    

    >> Share

    
    
12. MUNCK F, Jensen MB, Vejborg I, Gerlach MK, et al
    ASO Visual Abstract: Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment-A Register-Based Study.
    Ann Surg Oncol. 2024 Jul 16. doi: 10.1245/s10434-024-15752.
    

    >> Share

    
    
13. IWAI Y, Perez-Rojas S, Thomas SM, Tadros AB, et al
    ASO Visual Abstract: Guideline-Concordant Surgical Care for Lobular Versus Ductal Inflammatory Breast Cancer.
    Ann Surg Oncol. 2024 Jul 15. doi: 10.1245/s10434-024-15691.
    

    >> Share

    
    
14. BHIMANI F, Feldman S, Cavalli A, Chen Y, et al
    ASO Visual Abstract: Axillary Reverse Mapping Aids in Reducing the Rates of Breast Cancer-Related Lymphedema in Underserved Ethnically Diverse Population.
    Ann Surg Oncol. 2024 Jul 15. doi: 10.1245/s10434-024-15832.
    

    >> Share

    
    

    
    BMC Cancer

15. TANG H, Zhang W, Shen H, Tang H, et al
    A protocol for a multidisciplinary early intervention during chemotherapy to improve dietary management behavior in breast cancer patients: a two-arm, single-center randomized controlled trial.
    BMC Cancer. 2024;24:859.
    

    >> Share

    
    
16. SOHRABEI S, Moghaddasi H, Hosseini A, Ehsanzadeh SJ, et al
    Investigating the effects of artificial intelligence on the personalization of breast cancer management: a systematic study.
    BMC Cancer. 2024;24:852.
    

    >> Share

    
    
17. CHRISTINE D, Christian SF, Ricarda K, Christine K, et al
    Risk factors for residual fibroglandular breast tissue following a mastectomy - an overview and retrospective cohort study.
    BMC Cancer. 2024;24:856.
    

    >> Share

    
    
18. JIA L, Peng J, Sun N, Chen H, et al
    Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.
    BMC Cancer. 2024;24:850.
    

    >> Share

    
    
19. DAMTIE Z, Cherie N, Agidew MM
    Breast cancer preventive practices and associated factors among reproductive age women in Wadila District, North East Ethiopia: community based cross-sectional study.
    BMC Cancer. 2024;24:843.
    

    >> Share

    
    

    
    Breast Cancer

20. ALTUNDAG K
    Does axillary lymph node recurrence breast cancer subtype information matter for prognosis estimation?
    Breast Cancer. 2024 Jul 20. doi: 10.1007/s12282-024-01620.
    

    >> Share

    
    
21. HU Z, Lai C, Liu H, Man J, et al
    Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort.
    Breast Cancer. 2024 Jul 19. doi: 10.1007/s12282-024-01619.
    

    >> Share

    
    
22. SHIBATA A, Tamura N, Kinowaki K, Nishikawa A, et al
    Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
    Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01616.
    

    >> Share

    
    
23. HOSONAGA M, Habano E, Arakawa H, Kaneko K, et al
    Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
    Breast Cancer. 2024 Jul 17. doi: 10.1007/s12282-024-01612.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

24. PELLIZZARI S, Athwal H, Bonvissuto AC, Parsyan A, et al
    Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:341-346.
    

    >> Share

    
    

    
    Breast Cancer Res

25. MBURU W, Guo C, Tian Y, Koka H, et al
    Associations between quantitative measures of mammographic density and terminal ductal lobular unit involution in Chinese breast cancer patients.
    Breast Cancer Res. 2024;26:116.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

26. FOLDI J, Blenman KRM, Marczyk M, Gunasekharan V, et al
    Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.
    Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07426.
    

    >> Share

    
    
27. BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al
    Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
    Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07427.
    

    >> Share

    
    
28. PHILLIPS SM, Starikovsky J, Solk P, Desai R, et al
    Feasibility and preliminary effects of the Fit2ThriveMB pilot physical activity promotion intervention on physical activity and patient reported outcomes in individuals with metastatic breast cancer.
    Breast Cancer Res Treat. 2024 Jul 16. doi: 10.1007/s10549-024-07432.
    

    >> Share

    
    
29. SATO T, Oshi M, Huang JL, Chida K, et al
    CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Breast Cancer Res Treat. 2024 Jul 17. doi: 10.1007/s10549-024-07434.
    

    >> Share

    
    
30. ZHOU K, Zhang M, Zhai D, Wang Z, et al
    Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers.
    Breast Cancer Res Treat. 2024 Jul 19. doi: 10.1007/s10549-024-07437.
    

    >> Share

    
    

    
    Cancer

31. DENT S, Tumlinson R, Guha A, Moore H, et al
    Breast cancer risk reduction: Beyond pharmacologic intervention.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35442.
    

    >> Share

    
    
32. CHUNG HC, Saada-Bouzid E, Longo F, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35387.
    

    >> Share

    
    
33. NIERENGARTEN MB
    Inequities in breast cancer from prevention through supportive care.
    Cancer. 2024;130:2570.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

34. ISLAM MS, Akter F, Rahman MM, Rafe MR, et al
    Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients.
    Cancer Chemother Pharmacol. 2024 Jul 16. doi: 10.1007/s00280-024-04700.
    

    >> Share

    
    
35. MALHI V, Nowicka M, Chen YC, Agarwal P, et al
    UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
    Cancer Chemother Pharmacol. 2024;94:117-122.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

36. ANG BH, Teo SH, Ho WK
    Systematic review and meta-analysis of lifestyle and reproductive factors associated with risk of breast cancer in Asian women.
    Cancer Epidemiol Biomarkers Prev. 2024.
    

    >> Share

    
    
37. NORRIS RP, Dew R, Greystoke A, Cresti N, et al
    Socio-demographic disparities in HER2+ breast cancer trastuzumab receipt: An English population-based study.
    Cancer Epidemiol Biomarkers Prev. 2024.
    

    >> Share

    
    

    
    Cancer Res

38. HILLIS AL, Martin TD, Manchester HE, Hogstrom J, et al
    Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer.
    Cancer Res. 2024 Jul 18. doi: 10.1158/0008-5472.CAN-24-0970.
    

    >> Share

    
    

    
    Clin Breast Cancer

39. ZENG F, Cai W, Lin L, Chen C, et al
    Development of a Preoperative Prediction Model Based on Spectral CT to Evaluate Axillary Lymph Node With Macrometastases in Clinical T1/2N0 Invasive Breast Cancer.
    Clin Breast Cancer. 2024 Jun 18:S1526-8209(24)00174.
    

    >> Share

    
    
40. CALDEIRA IDS, Giovanini G, Adorno LF, Fernandes D, et al
    Antiapoptotic and Prometastatic Roles of Cytokine FAM3B in Triple-Negative Breast Cancer.
    Clin Breast Cancer. 2024 Jun 22:S1526-8209(24)00173.
    

    >> Share

    
    
41. LI X, Yang L, Jiang F, Jiao X, et al
    Integration of Radiomics and Immune-Related Genes Signatures for Predicting Axillary Lymph Node Metastasis in Breast Cancer.
    Clin Breast Cancer. 2024 Jun 25:S1526-8209(24)00179.
    

    >> Share

    
    

    
    Clin Cancer Res

42. SUN X, Kennedy LC, Gonzalez-Ericsson PI, Sanchez V, et al
    Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohort.
    Clin Cancer Res. 2024 Jul 15. doi: 10.1158/1078-0432.CCR-24-1286.
    

    >> Share

    
    

    
    Eur J Cancer

43. MARTINS-BRANCO D, Nader-Marta G, Molinelli C, Ameye L, et al
    Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
    Eur J Cancer. 2024;208:114195.
    

    >> Share

    
    

    
    Eur J Surg Oncol

44. GEDFEW M, Getie A, Akalu TY, Ayenew T, et al
    Recurrence and associated factors of breast cancer among women in sub saharan africa, systematic review and meta-analysis.
    Eur J Surg Oncol. 2024;50:108528.
    

    >> Share

    
    

    
    Eur Radiol

45. KLEIN WOLTERINK F, Ab Mumin N, Appelman L, Derks-Rekers M, et al
    Diagnostic performance of 3D automated breast ultrasound (3D-ABUS) in a clinical screening setting-a retrospective study.
    Eur Radiol. 2024;34:5451-5460.
    

    >> Share

    
    
46. SCHIAFFINO S, Cozzi A, Clauser P, Giannotti E, et al
    Current use and future perspectives of contrast-enhanced mammography (CEM): a survey by the European Society of Breast Imaging (EUSOBI).
    Eur Radiol. 2024;34:5439-5450.
    

    >> Share

    
    
47. PULIDO-CARMONA C, Romero-Martin S, Raya-Povedano JL, Cara-Garcia M, et al
    Interval cancer in the Cordoba Breast Tomosynthesis Screening Trial (CBTST): comparison of digital breast tomosynthesis plus digital mammography to digital mammography alone.
    Eur Radiol. 2024;34:5427-5438.
    

    >> Share

    
    

    
    Gene

48. GHALI RM, Zaied S, Daldoul A, Kanabekova P, et al
    Association between Toll-like receptor 2 rs4696483 and rs1898830 polymorphisms and the risk of triple-negative breast cancer.
    Gene. 2024 Jul 17:148773. doi: 10.1016/j.gene.2024.148773.
    

    >> Share

    
    

    
    Histopathology

49. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    

    >> Share

    
    

    
    Int J Cancer

50. BARNES I, Garcia-Closas M, Gathani T, Sweetland S, et al
    A comparative analysis of risk factor associations with interval and screen-detected breast cancers: A large UK prospective study.
    Int J Cancer. 2024;155:979-987.
    

    >> Share

    
    

    
    J Clin Oncol

51. KATZ SJ, Abrahamse P, Furgal A, Hodan R, et al
    Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
    J Clin Oncol. 2024 Jul 15:JCO2400122. doi: 10.1200/JCO.24.00122.
    

    >> Share

    
    
52. MATIKAS A, Mobus V, Greil R, Andersson A, et al
    Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
    J Clin Oncol. 2024 Jul 17:JCO2400178. doi: 10.1200/JCO.24.00178.
    

    >> Share

    
    

    
    J Natl Cancer Inst

53. HURSON AN, Ahearn TU, Koka H, Jenkins BD, et al
    Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.
    J Natl Cancer Inst. 2024 Jul 17:djae172. doi: 10.1093.
    

    >> Share

    
    

    
    J Pathol

54. CHEN M, van den Tempel N, Bhattacharya A, Yu S, et al
    Functional ex vivo DNA fibre assay to measure replication dynamics in breast cancer tissue.
    J Pathol. 2024 Jul 18. doi: 10.1002/path.6328.
    

    >> Share

    
    

    
    J Surg Oncol

55. BOLAND MR
    Modern management of the axilla.
    J Surg Oncol. 2024;130:23-28.
    

    >> Share

    
    
56. UPADHYAY N, Wolska J
    Imaging the dense breast.
    J Surg Oncol. 2024;130:29-35.
    

    >> Share

    
    
57. GARAYUA-CRUZ L, Broida SE, Okuno SH, Robinson SI, et al
    Outcomes of non-angiosarcoma radiation-associated soft tissue sarcomas of the chest.
    J Surg Oncol. 2024;130:56-63.
    

    >> Share

    
    
58. CHEN C, Tseng J, Amersi F, Silberman AW, et al
    Second primary malignancies in women with breast cancer.
    J Surg Oncol. 2024 Jul 19. doi: 10.1002/jso.27785.
    

    >> Share

    
    
59. KELLEY K, Sener SF
    Who still needs surgical staging of the axilla for invasive breast cancer?
    J Surg Oncol. 2024 Jun 21. doi: 10.1002/jso.27753.
    

    >> Share

    
    

    
    Mod Pathol

60. RAMMAL R, Goel K, Motanagh SA, Carter GJ, et al
    Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Mod Pathol. 2024;37:100517.
    

    >> Share

    
    

    
    NPJ Breast Cancer

61. FASCHING PA, Hu C, Hart SN, Ruebner M, et al
    Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.
    NPJ Breast Cancer. 2024;10:57.
    

    >> Share

    
    
62. KIM Y, Yeom CW, Lee HJ, Kim JH, et al
    Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial.
    NPJ Breast Cancer. 2024;10:59.
    

    >> Share

    
    
63. PAN JW, Tan ZC, Ng PS, Zabidi MMA, et al
    Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer.
    NPJ Breast Cancer. 2024;10:60.
    

    >> Share

    
    

    
    Oncology

64. KOVACOVA M, Hlavac V, Kozevnikovova R, Raus K, et al
    Artificial Intelligence-driven Prediction Revealed CFTR Associated With Therapy Outcome Of Breast Cancer: A Feasibility Study.
    Oncology. 2024 Jul 18. doi: 10.1159/000540395.
    

    >> Share

    
    

    
    PLoS One

65. JENKINS V, Habibi R, Hall V, Leonard P, et al
    Roll-out of an educational workshop to improve knowledge and self-confidence of healthcare professionals engaged in mainstreaming of breast cancer genetics.
    PLoS One. 2024;19:e0307301.
    

    >> Share

    
    
66. GEREMEW H, Golla EB, Simegn MB, Abate A, et al
    Late-stage diagnosis: The driving force behind high breast cancer mortality in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0307283.
    

    >> Share

    
    
67. WANG X, Dai Z, Zhu X, Li Y, et al
    Effects of mindfulness-based stress reduction on quality of life of breast cancer patient: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0306643.
    

    >> Share

    
    
68. MON AM, Craig MacKinnon A Jr, Traktman P
    Correction: Overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells.
    PLoS One. 2024;19:e0307693.
    

    >> Share

    
    
69. PATRA A, Ali SS, Devi NM, Qadeer AS, et al
    Prevalence of BRCA mutation in breast and ovarian cancer among women in India: A systematic review and meta-analysis protocol.
    PLoS One. 2024;19:e0306612.
    

    >> Share

    
    
70. JUNG M, Nicholas N, Grindrod S, Dritschilo A, et al
    Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth.
    PLoS One. 2024;19:e0306168.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

71. ZIN I, China A, Khan K, Nag JK, et al
    AKT-dependent nuclear localization of EPRS1 activates PARP1 in breast cancer cells.
    Proc Natl Acad Sci U S A. 2024;121:e2303642121.
    

    >> Share

    
    

    
    Radiology

72. MULLER-FRANZES G, Khader F, Tayebi Arasteh S, Huck L, et al
    Intraindividual Comparison of Different Methods for Automated BPE Assessment at Breast MRI: A Call for Standardization.
    Radiology. 2024;312:e232304.
    

    >> Share

    
    

    
    Radiother Oncol

73. BOERSMA LJ, Bijker N, Stam MR
    Reporting breast cancer radiation therapy details in studies and daily practice: Nice-to-have or a must-have?
    Radiother Oncol. 2024 Jul 17:110429. doi: 10.1016/j.radonc.2024.110429.
    

    >> Share

    
    
74. ALKNER S, Wieslander E, Lundstedt D, Berg M, et al
    Quality assessment of radiotherapy in the prospective randomized SENOMAC trial.
    Radiother Oncol. 2024;197:110372.
    

    >> Share

    
    
75. FRANCESCHINI D, Teriaca MA, Mancosu P, Bertolini A, et al
    Prospective phase II trial on ablative stereotactic body radiation therapy (SBRT) for medically inoperable thoracic nodes metastases.
    Radiother Oncol. 2024;197:110335.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share